-
Something wrong with this record ?
Prediction of treatment response in patients with locally advanced cervical cancer using midtreatment PET/MRI during concurrent chemoradiotherapy
R. Vojtíšek, J. Baxa, P. Kovářová, A. Almortaza, P. Hošek, E. Sukovská, R. Tupý, J. Ferda, J. Fínek
Language English Country Germany
Document type Comparative Study, Journal Article
Grant support
CZ.02.1.01/0.0/0.0/17_048/0007280)
Lékařská Fakulta v Plzni, Univerzita Karlova
NLK
ProQuest Central
from 1997-01-01 to 1 year ago
Medline Complete (EBSCOhost)
from 2006-08-01 to 1 year ago
Nursing & Allied Health Database (ProQuest)
from 1997-01-01 to 1 year ago
Health & Medicine (ProQuest)
from 1997-01-01 to 1 year ago
Public Health Database (ProQuest)
from 1997-01-01 to 1 year ago
- MeSH
- Antineoplastic Agents, Alkylating therapeutic use MeSH
- Brachytherapy MeSH
- Chemoradiotherapy * MeSH
- Cisplatin therapeutic use MeSH
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Lymphatic Metastasis MeSH
- Magnetic Resonance Imaging * MeSH
- Multimodal Imaging * MeSH
- Uterine Cervical Neoplasms diagnostic imaging metabolism pathology therapy MeSH
- Lymphatic Irradiation MeSH
- Area Under Curve MeSH
- Image Processing, Computer-Assisted MeSH
- Positron-Emission Tomography * MeSH
- Prognosis MeSH
- Radiotherapy, Intensity-Modulated MeSH
- ROC Curve MeSH
- Aged MeSH
- Carcinoma, Squamous Cell diagnostic imaging metabolism pathology therapy MeSH
- Neoplasm Staging methods MeSH
- Tumor Burden MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Comparative Study MeSH
PURPOSE: We aimed to find metabolic, functional or morphological characteristics of the tumor predicting failure to achieve complete metabolic remission (CMR) by the midtreatment PET/MRI (positron emission tomography/magnetic resonance imaging) in cervical cancer patients. METHODS: We evaluated 66 patients treated between August 2015 and November 2019 who underwent pretreatment staging, subsequent midtreatment evaluation, and definitive restaging 3 months after completing the whole treatment, all using PET/MRI. The pretreatment parameters (pre-SUVmax, pre-SUVmean, pre-MTV, pre-MTV‑S, pre-TLG, pre-TLG‑S [SUV: standard uptake value, MTV: metabolic tumor volume, TLG: total lesion glycolysis]), and the midtreatment parameters at week 5 during chemoradiotherapy (mid-SUVmax, mid-SUVmean, mid-MTV, mid-MTV‑S, mid-TLG and mid-TLG-S) were recorded. The value of ADC (apparent diffusion coefficient) was also measured. Furthermore, we recorded absolute and relative changes in all parameters-∆ and ∆%. We divided the whole group of patients into "responders" (CMR) and "non-responders" (non-CMR), and compared them on the basis of the parameters from pre-PET/MRI and mid-PET/MRI. RESULTS: A statistically significant difference in the evaluated parameters between responders and non-responders was found for the following parameters: mid-MTV, mid-TLG, mid-TLG‑S, mid-MTV‑S, mid-tumor size, and ∆%SUVmax. According to the ROC (receiver operating characteristic) analysis, mid-MTV‑S showed the best albeit moderate discrimination ability for the prediction of non-CMR. Significant mutual correlations of all variables, in particular between mid-MTV‑S and mid-TLG‑S and between mid-MTV and mid-TLG, were found (all p < 0.05). CONCLUSION: Our study confirmed that when using the midtreatment PET/MRI we are able to identify metabolic parameters having the discrimination ability for the prediction of non-CMR. In particular mid-MTV‑S, mid-MTV, mid-tumor size, mid-TLG‑S, mid-TLG and ∆%SUVmax.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21025700
- 003
- CZ-PrNML
- 005
- 20211026133602.0
- 007
- ta
- 008
- 211013s2021 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00066-020-01740-7 $2 doi
- 035 __
- $a (PubMed)33492444
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Vojtíšek, Radovan $u Department of Oncology and Radiotherapy, Charles University in Prague, Faculty of Medicine and University Hospital in Pilsen, alej Svobody 80, 30460, Pilsen, Czech Republic. vojtisekr@fnplzen.cz
- 245 10
- $a Prediction of treatment response in patients with locally advanced cervical cancer using midtreatment PET/MRI during concurrent chemoradiotherapy / $c R. Vojtíšek, J. Baxa, P. Kovářová, A. Almortaza, P. Hošek, E. Sukovská, R. Tupý, J. Ferda, J. Fínek
- 520 9_
- $a PURPOSE: We aimed to find metabolic, functional or morphological characteristics of the tumor predicting failure to achieve complete metabolic remission (CMR) by the midtreatment PET/MRI (positron emission tomography/magnetic resonance imaging) in cervical cancer patients. METHODS: We evaluated 66 patients treated between August 2015 and November 2019 who underwent pretreatment staging, subsequent midtreatment evaluation, and definitive restaging 3 months after completing the whole treatment, all using PET/MRI. The pretreatment parameters (pre-SUVmax, pre-SUVmean, pre-MTV, pre-MTV‑S, pre-TLG, pre-TLG‑S [SUV: standard uptake value, MTV: metabolic tumor volume, TLG: total lesion glycolysis]), and the midtreatment parameters at week 5 during chemoradiotherapy (mid-SUVmax, mid-SUVmean, mid-MTV, mid-MTV‑S, mid-TLG and mid-TLG-S) were recorded. The value of ADC (apparent diffusion coefficient) was also measured. Furthermore, we recorded absolute and relative changes in all parameters-∆ and ∆%. We divided the whole group of patients into "responders" (CMR) and "non-responders" (non-CMR), and compared them on the basis of the parameters from pre-PET/MRI and mid-PET/MRI. RESULTS: A statistically significant difference in the evaluated parameters between responders and non-responders was found for the following parameters: mid-MTV, mid-TLG, mid-TLG‑S, mid-MTV‑S, mid-tumor size, and ∆%SUVmax. According to the ROC (receiver operating characteristic) analysis, mid-MTV‑S showed the best albeit moderate discrimination ability for the prediction of non-CMR. Significant mutual correlations of all variables, in particular between mid-MTV‑S and mid-TLG‑S and between mid-MTV and mid-TLG, were found (all p < 0.05). CONCLUSION: Our study confirmed that when using the midtreatment PET/MRI we are able to identify metabolic parameters having the discrimination ability for the prediction of non-CMR. In particular mid-MTV‑S, mid-MTV, mid-tumor size, mid-TLG‑S, mid-TLG and ∆%SUVmax.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a alkylační protinádorové látky $x terapeutické užití $7 D018906
- 650 _2
- $a plocha pod křivkou $7 D019540
- 650 _2
- $a brachyterapie $7 D001918
- 650 _2
- $a spinocelulární karcinom $x diagnostické zobrazování $x metabolismus $x patologie $x terapie $7 D002294
- 650 12
- $a chemoradioterapie $7 D059248
- 650 _2
- $a cisplatina $x terapeutické užití $7 D002945
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a počítačové zpracování obrazu $7 D007091
- 650 _2
- $a ozařování lymfatického systému $7 D015182
- 650 _2
- $a lymfatické metastázy $7 D008207
- 650 12
- $a magnetická rezonanční tomografie $7 D008279
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a multimodální zobrazování $7 D064847
- 650 _2
- $a staging nádorů $x metody $7 D009367
- 650 12
- $a pozitronová emisní tomografie $7 D049268
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a ROC křivka $7 D012372
- 650 _2
- $a radioterapie s modulovanou intenzitou $7 D050397
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a tumor burden $7 D047368
- 650 _2
- $a nádory děložního čípku $x diagnostické zobrazování $x metabolismus $x patologie $x terapie $7 D002583
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Baxa, Jan $u Department of Imaging Methods, Charles University in Prague, Faculty of Medicine and University Hospital in Pilsen, alej Svobody 80, 30460, Pilsen, Czech Republic
- 700 1_
- $a Kovářová, Petra $u Department of Oncology and Radiotherapy, Charles University in Prague, Faculty of Medicine and University Hospital in Pilsen, alej Svobody 80, 30460, Pilsen, Czech Republic
- 700 1_
- $a Almortaza, Amira $u Department of Imaging Methods, Charles University in Prague, Faculty of Medicine and University Hospital in Pilsen, alej Svobody 80, 30460, Pilsen, Czech Republic
- 700 1_
- $a Hošek, Petr $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, alej Svobody 76, 32300, Pilsen, Czech Republic
- 700 1_
- $a Sukovská, Emília $u Department of Oncology and Radiotherapy, Charles University in Prague, Faculty of Medicine and University Hospital in Pilsen, alej Svobody 80, 30460, Pilsen, Czech Republic
- 700 1_
- $a Tupý, Radek $u Department of Imaging Methods, Charles University in Prague, Faculty of Medicine and University Hospital in Pilsen, alej Svobody 80, 30460, Pilsen, Czech Republic
- 700 1_
- $a Ferda, Jiří $u Department of Imaging Methods, Charles University in Prague, Faculty of Medicine and University Hospital in Pilsen, alej Svobody 80, 30460, Pilsen, Czech Republic
- 700 1_
- $a Fínek, Jindřich $u Department of Oncology and Radiotherapy, Charles University in Prague, Faculty of Medicine and University Hospital in Pilsen, alej Svobody 80, 30460, Pilsen, Czech Republic
- 773 0_
- $w MED00010658 $t Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] $x 1439-099X $g Roč. 197, č. 6 (2021), s. 494-504
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33492444 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20211013 $b ABA008
- 991 __
- $a 20211026133608 $b ABA008
- 999 __
- $a ok $b bmc $g 1714649 $s 1146207
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 197 $c 6 $d 494-504 $e 20210125 $i 1439-099X $m Strahlentherapie und Onkologie $n Strahlenther Onkol $x MED00010658
- GRA __
- $a CZ.02.1.01/0.0/0.0/17_048/0007280) $p Lékařská Fakulta v Plzni, Univerzita Karlova
- LZP __
- $a Pubmed-20211013